Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Oxaliplatin in metastatic colorectal cancer: Does hepatic arterial infusion reduce sensitive neuropathy compared to the intravenous route?
Authors
Marine Valery
Gustave Roussy, Villejuif, France
Marine Valery , Marie Laure Tanguy , Valérie Boige , Cristina Smolenschi , Antoine Hollebecque , Alina Fuerea , Caroline Klotz-Prieux , Leonor Benhaim , Thierry Debaere , Maximiliano Gelli , Lambros Tselikas , Michel Ducreux , David Malka
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
DOI
10.1200/JCO.2022.40.4_suppl.095
Abstract #
95
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase Ib adaptive study of dasatinib for the prevention of oxaliplatin-induced neuropathy in patients with metastatic colorectal cancer receiving FOLFOX chemotherapy and bevacizumab.
First Author: Anne M. Noonan
Poster
2015 Gastrointestinal Cancers Symposium
Triplet chemotherapy (TC) with FOLFIRINOX regimen in metastatic colorectal cancer (mCRC): Experience of two French centres.
First Author: Emmanuelle Samalin
Poster
2014 Gastrointestinal Cancers Symposium
A phase II study of cetuximab (cet) and mFOLFOX6 in metastatic colorectal cancer (mCRC) (JACCRO CC-05).
First Author: Tatsuro Yamaguchi
Poster
2012 ASCO Annual Meeting
Triplet chemotherapy (TC) with FOLFIRINOX regimen in metastatic colorectal cancer (mCRC): Experience of the Val d'Aurelle Center.
First Author: Emmanuelle Samalin